100 related articles for article (PubMed ID: 31932457)
21. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
22. A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth.
Farnsworth RH; Karnezis T; Shayan R; Matsumoto M; Nowell CJ; Achen MG; Stacker SA
Cancer Res; 2011 Oct; 71(20):6547-57. PubMed ID: 21868759
[TBL] [Abstract][Full Text] [Related]
23. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
24. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice.
Ghalamfarsa G; Rastegari A; Atyabi F; Hassannia H; Hojjat-Farsangi M; Ghanbari A; Anvari E; Mohammadi J; Azizi G; Masjedi A; Yousefi M; Yousefi B; Hadjati J; Jadidi-Niaragh F
J Cell Physiol; 2018 Oct; 233(10):7165-7177. PubMed ID: 29741783
[TBL] [Abstract][Full Text] [Related]
25. Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases in cervix cancer.
Chaudary N; Milosevic M; Hill RP
Gynecol Oncol; 2011 Nov; 123(2):393-400. PubMed ID: 21839498
[TBL] [Abstract][Full Text] [Related]
26. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
27. VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.
Alitalo AK; Proulx ST; Karaman S; Aebischer D; Martino S; Jost M; Schneider N; Bry M; Detmar M
Cancer Res; 2013 Jul; 73(14):4212-21. PubMed ID: 23695550
[TBL] [Abstract][Full Text] [Related]
28. Lymphotoxin-α promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3-dependent manner.
Yang JG; Wang WM; Xia HF; Yu ZL; Li HM; Ren JG; Chen G; Wang BK; Jia J; Zhang W; Zhao YF
Int J Cancer; 2019 Sep; 145(5):1358-1370. PubMed ID: 30785217
[TBL] [Abstract][Full Text] [Related]
29. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
30. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
[TBL] [Abstract][Full Text] [Related]
31. Expression of VEGFR3 in glioma endothelium correlates with tumor grade.
Grau SJ; Trillsch F; Herms J; Thon N; Nelson PJ; Tonn JC; Goldbrunner R
J Neurooncol; 2007 Apr; 82(2):141-50. PubMed ID: 17115285
[TBL] [Abstract][Full Text] [Related]
32. VEGFR3 inhibition chemosensitizes lung adenocarcinoma A549 cells in the tumor-associated macrophage microenvironment through upregulation of p53 and PTEN.
Li Y; Weng Y; Zhong L; Chong H; Chen S; Sun Y; Li W; Shi Q
Oncol Rep; 2017 Nov; 38(5):2761-2773. PubMed ID: 29048623
[TBL] [Abstract][Full Text] [Related]
33. Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma.
Lauenborg B; Christensen L; Ralfkiaer U; Kopp KL; Jønson L; Dabelsteen S; Bonefeld CM; Geisler C; Gjerdrum LM; Zhang Q; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
Oncotarget; 2015 Jun; 6(17):15235-49. PubMed ID: 25915535
[TBL] [Abstract][Full Text] [Related]
34. miR-342-5p Is a Notch Downstream Molecule and Regulates Multiple Angiogenic Pathways Including Notch, Vascular Endothelial Growth Factor and Transforming Growth Factor β Signaling.
Yan XC; Cao J; Liang L; Wang L; Gao F; Yang ZY; Duan JL; Chang TF; Deng SM; Liu Y; Dou GR; Zhang J; Zheng QJ; Zhang P; Han H
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26857067
[TBL] [Abstract][Full Text] [Related]
35. GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment.
De Francesco EM; Sims AH; Maggiolini M; Sotgia F; Lisanti MP; Clarke RB
Breast Cancer Res; 2017 Dec; 19(1):129. PubMed ID: 29212519
[TBL] [Abstract][Full Text] [Related]
36. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
37. TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling.
Ji H; Cao R; Yang Y; Zhang Y; Iwamoto H; Lim S; Nakamura M; Andersson P; Wang J; Sun Y; Dissing S; He X; Yang X; Cao Y
Nat Commun; 2014 Sep; 5():4944. PubMed ID: 25229256
[TBL] [Abstract][Full Text] [Related]
38. The lymphotoxin β receptor is a potential therapeutic target in renal inflammation.
Seleznik G; Seeger H; Bauer J; Fu K; Czerkowicz J; Papandile A; Poreci U; Rabah D; Ranger A; Cohen CD; Lindenmeyer M; Chen J; Edenhofer I; Anders HJ; Lech M; Wüthrich RP; Ruddle NH; Moeller MJ; Kozakowski N; Regele H; Browning JL; Heikenwalder M; Segerer S
Kidney Int; 2016 Jan; 89(1):113-26. PubMed ID: 26398497
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of lymphoma vascularization and dissemination by estrogen receptor β agonists.
Yakimchuk K; Hasni MS; Guan J; Chao MP; Sander B; Okret S
Blood; 2014 Mar; 123(13):2054-61. PubMed ID: 24470591
[TBL] [Abstract][Full Text] [Related]
40. Molecular controls of lymphatic VEGFR3 signaling.
Deng Y; Zhang X; Simons M
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):421-9. PubMed ID: 25524775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
